Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the phase III KEYNOTE-040 trial in head and neck cancer.

The KEYNOTE-040 trial evaluated pembrolizumab (Keytruda) versus standard of care in patients with recurrent or metatstaic head and neck squamous cell carcinoma.

This was the first effort in a randomized setting to demonstrate benefit, though statistically, it did not meet its endpoint.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Head & Neck Cancers

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer. 

Dr. Cohen Discusses the KEYNOTE-040 Trial in Head and Neck Cancer